I'm sure if you call IDIX ceo/cfo they may be able to help you.
That won't be necessary. The value driver for VRUS is their lead nuke PSI-7977 which is a pyrimidine nucleotide analog which IDIX has yet to bring forward into clinical testing. If there's an IP issue my guess it's the other way around.